Incyte stock (US45337C1027): Patent win secures Jakafi protection

Incyte Corporation won a significant patent infringement case against Hikma Pharmaceuticals. On October 27, 2025, the U.S. District Court in Delaware issued a consent judgment and permanent injunction, prohibiting Hikma from selling its generic version of Jakafi (ruxolitinib) until all five relevant patents expire, ad-hoc-news.de as of October 2025. This safeguards Incyte's top revenue driver amid ongoing Hatch-Waxman litigation.

Incyte stock traded at $98.56 USD on Nasdaq on May 13, 2026, up 0.81% that day with bullish technical signals, Pluang as of May 2026. The patent protection extends Jakafi's market exclusivity, critical for US investors tracking biotech firms with strong oncology portfolios.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Incyte: core business model

Incyte is a Wilmington, Delaware-based biopharmaceutical company specializing in small-molecule drugs for oncology, inflammation, and autoimmunity. The firm develops precision medicines targeting unmet needs in hematologic malignancies and other serious diseases, Incyte.com as of 2026. Its pipeline emphasizes inhibitors like JAK, PI3K, and HDAC classes.

Listed on Nasdaq under ticker INCY, Incyte generates substantial revenue from the US market, making it relevant for American retail investors seeking exposure to innovative biotech without heavy reliance on large pharma partnerships for commercialization.

Main revenue and product drivers for Incyte

Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor, remains Incyte's cornerstone product, approved for myelofibrosis, polycythemia vera, and graft-versus-host disease. It drove the majority of 2024 revenues, with US sales forming the bulk, per company reports. The recent patent win ensures continued protection against generics.

Other contributors include Opzelura (ruxolitinib cream) for atopic dermatitis and Vitrakvi for NTRK fusion cancers. Incyte's strategy focuses on expanding labels and geographies while advancing mid-stage pipeline assets in solid tumors and autoimmune disorders.

Industry trends and competitive position

The oncology sector sees rising demand for targeted therapies amid aging populations and precision medicine advances. Incyte competes with firms like AbbVie and Regeneron in hematology but holds a niche in JAK inhibition, MarketBeat as of 2026. Patent cliffs pose risks, but the Jakafi ruling bolsters its moat.

Why Incyte matters for US investors

As a Nasdaq-listed biotech with primary revenue from FDA-approved drugs, Incyte offers US investors direct exposure to oncology innovation. Its Delaware headquarters and focus on US commercialization align with domestic market dynamics, including Medicare coverage for rare disease treatments.

Conclusion

The October 2025 patent victory underscores Incyte's commitment to defending its intellectual property around Jakafi, a vital revenue stream. While the stock showed modest gains recently, ongoing pipeline progress and label expansions will shape future performance. Investors should monitor upcoming earnings and regulatory updates for further clarity.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.